stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
124.40
19.26
−13.41%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) EPS (diluted)
GRAIL, Inc.'s EPS (diluted) for fiscal 2025 was −$11.11, compared with −$63.54 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$9.50. GRAIL, Inc. ranks 46th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$11.11 | — |
| FY2024 | −$63.54 | — |
| FY2023 | −$47.21 | — |
| FY2022 | −$173.89 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$2.21 | — |
| Jun 2026 | −$2.56 | — |
| Mar 2026 | −$2.29 | — |
| Dec 2025 | −$2.44 | — |
| 9 more quarters | Free account |
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ICLR ICON PLC compare | $5.81 |
| CDNA CareDx, Inc. compare | $2.39 |
| QGEN QIAGEN N.V. compare | $1.95 |
| VCYT Veracyte, Inc. compare | $1.55 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| SHC Sotera Health Company compare | $0.60 |
| RDNT RadNet, Inc. compare | −$0.27 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| GRAL GRAIL, Inc. | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GRAL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement